Skip to main content Back to Top
Advertisement

12/4/2019

Nimodipine Oral Solution

Products Affected - Description

    • Nymalize oral solution, Arbor, 30 mg/10 mL, unit-dose cup, 12 count, NDC 24338-0205-12
    • Nymalize oral solution, Arbor, 60 mg/20 mL, unit-dose cup, 12 count, NDC 24338-0200-12

Reason for the Shortage

    • Arbor Pharmaceuticals did not provide a reason for the shortage.

Available Products

    • Nymalize oral solution, Arbor, 60 mg/20 mL, 473 mL bottle, 1 count, NDC 24338-0200-16

Estimated Resupply Dates

    • Arbor Pharmaceuticals has Nymalize 30 mg/10 mL and 60 mg/20 mL cups on back order and the company cannot estimate a release date.

Safety

    • The contents of nimodipine capsules may be extracted into a syringe using an 18-gauge needle. Transfer the contents of the capsule to an oral syringe that is not compatible with intravenous (IV) connections to avoid accidental IV administration of nimodipine. The manufacturers of nimodipine capsules and the Institute for Safe Medication Practices (ISMP) both recommend labeling the syringe containing nimodipine for administration with the phrase, "For Oral Use Only." Once the contents are given via a nasogastric tube, wash the tube with 30 mL of 0.9% normal saline. More information can be found at the following links:
    • Nimodipine Capsule Manufacturer Package Inserts: https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=nimodipine&pagesize=200&page=1
    • ISMP Oral Syringe Featured Article: https://www.ismp.org/resources/using-oral-syringes-wont-necessarily-protect-against-inadvertent-iv-injection-oral

Updated

Updated December 4, 2019 by Leslie Jensen, PharmD, Drug Information Specialist. Created November 21, 2019 by Stephen Andrews, PharmD, BCPS, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins